查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924687

KRAS抑制剂市场依适应症、作用机制、突变类型、剂型、最终用户和通路划分－2026-2032年全球预测

KRAS Inhibitor Market by Indication, Mechanism Of Action, Mutation Type, Dosage Form, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

KRAS抑制剂市场预计到2025年将达到9.2385亿美元，到2026年将成长到9.6858亿美元，到2032年将达到12.7767亿美元，年复合成长率为4.74%。

关键市场统计数据
基准年 2025 9.2385亿美元
预计年份：2026年 9.6858亿美元
预测年份 2032 1,277,670,000 美元
复合年增长率 (%) 4.74%

展望未来，概述KRAS抑制剂的科学突破、临床路径、监管环境和策略重点。

经过数十年的科学挑战，KRAS抑制已成为标靶癌症治疗创新的重点。结构生物学的最新进展、药物发现平台的改进以及更具预测性的临床前模型，使得治疗方法能够选择性地靶向致癌性的KRAS突变，从而改变了临床医生和研发人员应对传统上难以治疗的癌症驱动因素的方式。随着该领域的不断发展，相关人员必须权衡加速的转化研究进展与临床异质性、支付方审查以及复杂的生产要求等现实因素。

深入剖析KRAS抑制剂的研发、商业性趋势、试验设计、伙伴关係模式以及重塑病患用药路径的变革性转变

KRAS抑制剂领域正经历着由科学、临床和商业性发展融合驱动的变革性转折点。首先，针对突变特异性结合位点的精准设计方法正在加速化合物从发现阶段转换到人体试验的过程。同时，与免疫疗法和路径调节剂的联合策略正在重新定义试验终点和队列选择。因此，申办方正迅速转向适应性试验设计，这种设计能够基于中间生物标记进行决策并富集队列，从而加快获得具有临床意义的结果。

深入分析2025年美国关税和贸易政策变化对KRAS抑制剂供应链、生产和定价趋势的影响

2025年源自美国的贸易政策变化和关税措施可能透过一系列营运和策略途径对KRAS抑制剂生态系统产生重大影响。关税调整若导致进口活性药物原料药、特殊试剂或关键生产设备的成本增加，可能会挤压利润空间，并促使关键生产环节回流至国内或近岸地区。为此，申办方和契约製造製造商可能会加快本地化策略，重新评估供应商选择计划，并优先考虑双重采购以降低关税和物流风险。

从临床、机制、突变、剂量、终端用户和管道等观点，揭示治疗方法差异化和推广应用的策略性细分洞察。

有效的市场区隔对于将科学差异转化为有针对性的开发和商业化路径至关重要。必须了解大肠直肠癌、非小细胞肺癌和动态的市场动态，因为肿瘤生物学、治疗前环境和诊断流程会影响不同适应症的临床试验实施和应用考量。根据作用机制，变构抑制剂、共用抑制剂和非共用抑制剂提供了不同的治疗方法，每种方法都有独特的安全性、给药策略和抗药性模式。根据突变类型，项目重点与G12C、G12D和G12V等关键驱动因素一致，而突变特异性疗效则决定了伴随诊断策略和患者族群选择方法。

影响临床试验、监管方式和病患准入的区域趋势：来自美洲、欧洲、中东和非洲以及亚太地区的亮点

区域差异对研发时间表、监管互动和市场准入途径有显着影响。在美洲，临床试验能力、完善的支付方体系和大规模的肿瘤网络使得基于生物标誌物筛选的患者队列能够快速招募，而报销谈判和卫生技术评估（HTA）的参与则对上市顺序和市场准入政策产生重大影响。在欧洲、中东和非洲，不同的监管标准、国家报销体系和诊断基础设施要求研发企业制定适应性强的打入市场策略，以适应区域性的HTA流程、共同支付结构和不同的临床证据要求。在亚太地区，多个市场的快速审批通道、不断扩展的精准诊断基础设施以及日益增长的肿瘤治疗能力既带来了机会，也带来了挑战。研发企业必须调整其申报策略和本地临床项目，以适应不同的核准途径和支付方标准。

公司层面视角：对KRAS专案的竞争定位、研发管线重点、合作伙伴关係、生产能力及商业化准备进行分析

公司层面的趋势是KRAS抑制剂近期市场发展的关键驱动因素。主要企业正透过聚焦产品线、优化药物化学方法以提高选择性和安全性，以及建立策略联盟来加速与联合治疗合作伙伴和诊断能力的对接，从而实现差异化竞争。一些公司正在投资扩大生产规模和签订长期原料药供应协议，以确保可靠的临床供应并为潜在的商业需求做好准备。另一些公司则优先采用精益外包模式，以保持柔软性并降低资本风险。

为产业领导者提供切实可行的建议，以加速KRAS开发、完善商业策略、儘早与支付方接洽并增强供应韧性。

行业领导者必须采取务实且优先的行动，将科学进步转化为对患者的持久影响。首先，将转化科学和临床试验设计与明确的监管和支付方证据要求一致，并进行能够产生有利于医保报销决策所需数据的研究。其次，实施稳健的供应链连续性计划，包括双重采购、本地生产评估和检验的应急库存水平，以降低地缘政治和关税相关风险。第三，促进与支付方的早期务实沟通，以确定价值来源、明确可接受的终点指标，并探索能够在整个价值链上共用风险的创新合约模式。

一套透明的调查方法，详细说明了资料收集方法、证据综合、相关人员访谈、临床试验映射和品质保证通讯协定。

本报告的分析遵循透明的调查方法，整合多方证据，以确保其可靠性和相关性。关键资讯来源包括同行评审文献、公开的监管文件、临床试验註册资讯以及有助于理解专案层面和机制的公司披露资讯。资讯来源，我们也对临床研究人员、生产专家和商业领袖进行了结构化访谈，以了解实际营运和前瞻性观点。在综合这些资讯时，我们优先考虑由多个独立资讯来源证实的资料点，并仔细进行交叉检验。

最终综合分析，提炼出KRAS投资与策略的科学进展、临床意义、商业化准备与策略要务。

总而言之，KRAS抑制剂的研发正处于一个转折点，结构生物学的突破和精密的临床策略正与商业性和营运的迫切需求交汇融合。科学进步使得针对特定突变的标靶化成为可能，但要真正造福患者，需要整合试验设计、生产能力、医保合作以及地域参与策略等各个环节。能够成功驾驭这些相互关联的领域的公司，将能够把转化医学的进展转化为永续的临床项目和可及的治疗方法。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：KRAS抑制剂市场（依适应症划分）

  • 大肠直肠癌
  • 非小细胞肺癌
  • 胰臟癌

9. KRAS抑制剂市场依作用机转划分

  • 变构抑制剂
  • 共用抑制剂
  • 共用抑制剂

第十章 按突变类型分類的KRAS抑制剂市场

  • G12C
  • G12D
  • G12V

第十一章 KRAS抑制剂市场按剂型划分

  • 注射液
  • 口服锭剂

第十二章 KRAS抑制剂市场（依最终用户划分）

  • 癌症治疗中心
  • 医院
  • 零售药房
  • 专科诊所

第十三章 KRAS抑制剂市场（依通路划分）

  • 离线
  • 在线的

第十四章 KRAS抑制剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 KRAS抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国KRAS抑制剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国KRAS抑制剂市场

第十八章：中国KRAS抑制剂市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen
  • AnBogen Therapeutics
  • Applied Pharmaceutical Science
  • AstraZeneca
  • Biond Biologics
  • Boehringer Ingelheim
  • BridgeBio Oncology Therapeutics
  • Bristol Myers Squibb
  • Cardiff Oncology, Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly
  • Elicio Therapeutics
  • Erasca
  • Frontier Medicines
  • GenFleet Therapeutics
  • Gritstone Bio
  • Immuneering Corporation
  • Innovent Bio
  • InventisBio
  • Jacobio Pharmaceuticals
  • Jiangsu Hansoh Pharmaceutical
  • Jiangsu Hengrui Medicine Co.
  • Merck
  • Mirati Therapeutics
  • Novartis
  • Quanta Therapeutics
  • Revolution Medicines
  • Roche
  • Suzhou Zelgen Biopharmaceuticals
  • Verastem Oncology
Product Code: MRR-7A380DA7C427

The KRAS Inhibitor Market was valued at USD 923.85 million in 2025 and is projected to grow to USD 968.58 million in 2026, with a CAGR of 4.74%, reaching USD 1,277.67 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 923.85 million
Estimated Year [2026] USD 968.58 million
Forecast Year [2032] USD 1,277.67 million
CAGR (%) 4.74%

A forward-looking introduction that frames KRAS inhibitor scientific breakthroughs, clinical translation pathways, regulatory landscape and strategic priorities

KRAS inhibition has emerged from decades of scientific challenge to become a focal point for targeted oncology innovation. Recent structural biology advances, improved drug-design platforms and more predictive preclinical models have enabled therapies that selectively target oncogenic KRAS mutations, changing how clinicians and developers approach historically intractable cancer drivers. As the field advances, stakeholders must reconcile accelerated translational progress with the realities of clinical heterogeneity, payer scrutiny and complex manufacturing requirements.

This introduction positions the reader to understand the multifaceted forces shaping KRAS inhibitor development today. It highlights the interplay between molecular design choices and clinical strategy, clarifies how mutation-specific efficacy translates to indication prioritization, and outlines the key operational considerations that influence progression from early-phase trials to broader clinical adoption. By framing the science alongside commercial and regulatory considerations, this opening establishes a practical lens through which subsequent sections interpret supply-chain dynamics, segmentation nuances, regional differences and company-level competitiveness, enabling executives to align scientific opportunity with executable business plans.

An incisive review of transformative shifts reshaping KRAS inhibitor R&D, commercial dynamics, trial designs, partnership models and patient access pathways

The KRAS inhibitor landscape is experiencing transformative shifts driven by converging scientific, clinical and commercial developments. First, precision design approaches that exploit unique mutant pockets have accelerated the transition of compounds from discovery into human testing, while combination strategies with immunotherapies and pathway modulators are redefining trial endpoints and cohort selection. As a result, sponsors are moving faster to adaptive trial designs that allow for interim biomarker-driven decisions and enriched cohorts, thereby shortening the path to clinically meaningful readouts.

Concurrently, commercial dynamics are evolving: payers and health systems increasingly demand robust comparative-effectiveness evidence, and licensing and partnership models are shifting toward risk-sharing and milestone-based agreements to spread development burden and accelerate global access. Manufacturing and supply chain planning have become strategic differentiators, with developers investing in scalable API routes and redundant production nodes. Taken together, these shifts require organizations to integrate translational science with pragmatic go-to-market strategies, emphasize cross-functional coordination, and prioritize early dialogue with regulators and payers to de-risk late-stage development and enable sustainable patient access.

A nuanced analysis of how United States tariffs and trade policy changes in 2025 could affect KRAS inhibitor supply chains, manufacturing and pricing dynamics

Trade policy changes and tariff actions originating from the United States in 2025 can exert meaningful influence on the KRAS inhibitor ecosystem through a series of operational and strategic channels. Tariff adjustments that increase costs for imported active pharmaceutical ingredients, specialized reagents, or critical manufacturing equipment create pressure on margins and can incentivize onshoring or nearshoring of key manufacturing steps. In response, sponsors and contract manufacturers may accelerate localization strategies, revise supplier qualification plans, and prioritize dual-sourcing to mitigate tariff and logistics exposure.

Beyond direct cost impacts, tariff-driven reconfiguration of supply chains can affect timelines for CMO scale-up, capital deployment for domestic capacity, and inventory strategies to ensure clinical trial continuity. Indirect effects may include renegotiated partnership terms as externalized cost structures shift commercial models, and a renewed emphasis on upstream process innovations that reduce reliance on tariff-impacted inputs. Importantly, regulatory compliance and quality oversight remain non-negotiable during any supply-chain transition, so organizations must balance speed with quality assurance. Ultimately, prudent planning-rooted in scenario analysis, early supplier engagement, and contingency manufacturing agreements-can preserve development timelines and maintain patient access while navigating trade-policy headwinds.

Strategic segmentation insights revealing clinical, mechanistic, mutational, dosage, end-user and channel perspectives on therapeutic differentiation and adoption

Meaningful segmentation is essential for translating scientific differentiation into targeted development and commercialization pathways. Based on Indication, market dynamics must be understood across Colorectal Cancer, Non-Small Cell Lung Cancer, and Pancreatic Cancer where tumor biology, prior treatment landscapes and diagnostic routines create distinct trial and uptake considerations. Based on Mechanism Of Action, therapeutic approaches differ among Allosteric Inhibitors, Covalent Inhibitors, and Non-Covalent Inhibitors, each presenting unique safety profiles, dosing strategies and resistance patterns. Based on Mutation Type, program focus aligns to predominant drivers such as G12C, G12D, and G12V, and mutation-specific efficacy dictates companion diagnostic strategies and patient-enrichment methods.

Further granularity comes from dosage and delivery considerations: Based on Dosage Form, formulations such as Injectable Solutions versus Oral Tablets affect administration settings, adherence expectations and distribution logistics. Based on End User, channels vary across Cancer Care Centers, Hospitals, Retail Pharmacies, and Specialty Clinics, shaping provider training, infusion capacity requirements and patient support models. Finally, Based on Distribution Channel, the dynamics of Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Specialty Pharmacy influence stocking policies, reimbursement pathways and last-mile delivery strategies. Integrating these segmentation lenses enables a coherent view of how clinical attributes translate into operational priorities and commercial approaches.

Regional spotlight on Americas, Europe, Middle East & Africa and Asia-Pacific dynamics shaping clinical trials, regulatory approaches and patient access

Regional nuance shapes development timelines, regulatory interactions and access pathways in meaningful ways. In the Americas, clinical trial capacity, established payer frameworks and large oncology networks enable rapid patient recruitment for biomarker-selected cohorts, while reimbursement negotiations and HTA engagements strongly influence launch sequencing and access policies. In Europe, Middle East & Africa, the mosaic of regulatory standards, national reimbursement systems and variable diagnostic infrastructure requires adaptive market-entry strategies that account for regional HTA processes, co-pay structures and differentiated clinical evidence expectations. In Asia-Pacific, accelerated regulatory pathways in several markets, expanding precision-diagnostics infrastructure and growing oncology treatment capacity present both an opportunity and a complexity: developers must calibrate dossier strategies and local clinical programs to accommodate diverse approval pathways and payer criteria.

Cross-region considerations also influence supply and manufacturing footprints, as regional regulatory standards and import/export constraints shape location decisions and inventory planning. Consequently, a regionalized approach that aligns clinical evidence generation with local regulatory expectations, engages payers early, and invests in diagnostic and provider education will enhance adoption and ensure more predictable patient access across these distinct geographies.

Company-level perspectives unpacking competitive positioning, pipeline focus, alliances, manufacturing capability and commercialization readiness for KRAS programs

Company-level dynamics are central to how the KRAS inhibitor landscape will evolve over the near term. Leading developers are differentiating through focused pipelines, optimized medicinal chemistry approaches that improve selectivity and safety, and strategic collaborations that accelerate access to combination partners or diagnostic capabilities. Several firms are investing in scale-up capacity and long-term API supply agreements to ensure reliable clinical supply and prepare for potential commercial demand, while others prioritize lean outsourcing models to maintain flexibility and limit capital exposure.

Partnership strategies range from co-development and licensing to catalytic R&D alliances with diagnostics providers and academic centers, reflecting an emphasis on shared risk and complementary capabilities. Competitive positioning also depends on the depth of clinical data packages, the clarity of biomarker-driven value propositions, and proven manufacturing robustness. For investors and strategic planners, assessing company strength requires careful evaluation of pipeline breadth, clinical evidence quality, strategic alliances, production readiness and commercialization capabilities, recognizing that execution across these domains ultimately determines the ability to convert scientific promise into accessible therapies.

Actionable recommendations for industry leaders to accelerate KRAS development, refine commercial strategies, engage payers early and fortify supply resilience

Industry leaders must adopt pragmatic, prioritized actions to translate scientific progress into sustained patient impact. First, align translational science and clinical trial design with clear regulatory and payer evidence needs so that trials generate the data required for favorable reimbursement decisions. Second, implement robust supply continuity plans that include dual sourcing, local manufacturing assessments and validated contingency inventory levels to mitigate geopolitical and tariff-related risks. Third, pursue early and pragmatic payer engagement to establish value drivers, clarify acceptable endpoints and explore innovative contracting models that share risk across the value chain.

Additionally, companies should invest in companion diagnostic strategies that ensure accurate patient identification and support rapid trial enrollment, while integrating real-world evidence plans to capture effectiveness and safety in broader populations. Stakeholders should also prioritize cross-functional commercialization readiness, including provider education, patient support infrastructure and distribution channel optimization. By sequencing these recommendations-evidence alignment, supply resilience, payer engagement, diagnostic integration and commercialization preparedness-organizations can reduce execution risk and accelerate patient access to KRAS-targeted therapies.

Transparent research methodology detailing data sourcing, evidence synthesis, stakeholder interviews, clinical trial mapping and quality assurance protocols

The analysis underpinning this report integrates multiple evidence streams and follows a transparent methodology to ensure reliability and relevance. Primary inputs include peer-reviewed literature, publicly available regulatory documents, clinical-trial registries and company disclosures that inform program-level and mechanistic understanding. These sources are complemented by structured interviews with clinical investigators, manufacturing experts and commercial leaders to capture operational realities and forward-looking perspectives. In synthesizing these inputs, careful attention was given to cross-validation, privileging data points corroborated by multiple independent sources.

Analytical methods include qualitative evidence synthesis, clinical-trial mapping to identify enrollment drivers and endpoint trends, and scenario-based supply-chain sensitivity analysis that examines how operational disruptions or tariff changes could affect continuity. Throughout, quality assurance protocols were applied to ensure traceability of evidence and to document assumptions. This methodological approach provides a robust foundation for the insights and recommendations presented, balancing scientific rigor with pragmatic considerations relevant to decision-makers.

Concluding synthesis distilling scientific progress, clinical implications, commercialization readiness and strategic imperatives for KRAS investment and strategy

In summary, KRAS inhibitor development is at an inflection point where structural biology breakthroughs and refined clinical strategies are converging with commercial and operational imperatives. Scientific progress has made mutation-specific targeting feasible, but realizing patient impact requires integrated approaches that align trial design, manufacturing capability, payer engagement and regional entry strategies. Companies that successfully navigate these interconnected domains will convert translational advances into durable clinical programs and accessible therapies.

Moving forward, decision-makers should emphasize evidence that meets regulatory and payer expectations, build resilient supply chains that account for trade and tariff volatility, and tailor regional strategies to local regulatory and diagnostic environments. The path to broader KRAS-targeted care depends as much on disciplined execution and strategic partnerships as it does on further scientific innovation. With disciplined alignment across science, operations and commercialization, stakeholders can create a clear, actionable roadmap to deliver optimized therapies to the patients who need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. KRAS Inhibitor Market, by Indication

  • 8.1. Colorectal Cancer
  • 8.2. Non-Small Cell Lung Cancer
  • 8.3. Pancreatic Cancer

9. KRAS Inhibitor Market, by Mechanism Of Action

  • 9.1. Allosteric Inhibitors
  • 9.2. Covalent Inhibitors
  • 9.3. Non-Covalent Inhibitors

10. KRAS Inhibitor Market, by Mutation Type

  • 10.1. G12C
  • 10.2. G12D
  • 10.3. G12V

11. KRAS Inhibitor Market, by Dosage Form

  • 11.1. Injectable Solutions
  • 11.2. Oral Tablets

12. KRAS Inhibitor Market, by End User

  • 12.1. Cancer Care Centers
  • 12.2. Hospitals
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Clinics

13. KRAS Inhibitor Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. KRAS Inhibitor Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. KRAS Inhibitor Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. KRAS Inhibitor Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States KRAS Inhibitor Market

18. China KRAS Inhibitor Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen
  • 19.6. AnBogen Therapeutics
  • 19.7. Applied Pharmaceutical Science
  • 19.8. AstraZeneca
  • 19.9. Biond Biologics
  • 19.10. Boehringer Ingelheim
  • 19.11. BridgeBio Oncology Therapeutics
  • 19.12. Bristol Myers Squibb
  • 19.13. Cardiff Oncology, Inc.
  • 19.14. Deciphera Pharmaceuticals
  • 19.15. Eli Lilly
  • 19.16. Elicio Therapeutics
  • 19.17. Erasca
  • 19.18. Frontier Medicines
  • 19.19. GenFleet Therapeutics
  • 19.20. Gritstone Bio
  • 19.21. Immuneering Corporation
  • 19.22. Innovent Bio
  • 19.23. InventisBio
  • 19.24. Jacobio Pharmaceuticals
  • 19.25. Jiangsu Hansoh Pharmaceutical
  • 19.26. Jiangsu Hengrui Medicine Co.
  • 19.27. Merck
  • 19.28. Mirati Therapeutics
  • 19.29. Novartis
  • 19.30. Quanta Therapeutics
  • 19.31. Revolution Medicines
  • 19.32. Roche
  • 19.33. Suzhou Zelgen Biopharmaceuticals
  • 19.34. Verastem Oncology

LIST OF FIGURES

  • FIGURE 1. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KRAS INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL KRAS INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS KRAS INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL KRAS INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. GCC KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. GCC KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. G7 KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. G7 KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. NATO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. NATO KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)